Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2002

View Archived Issues

New pharmacokinetic data reported for LY-450108 and LY-451395

SBIR grant supports development of second-generation angiostatin proteins for cancer

Kyorin increases investment in collaborative partner

Saegis broadens research collaboration with Johns Hopkins

Lotronex available under restricted use for women with diarrhea-predominant IBS

Eximias grants rights for Thymitaq to LG Life Sciences

Ivax to develop LMB-9

Amendment to Zavesca NDA to be filed

Vivus initiates trial of VI-0162 in premature ejaculation

AVI-4126 proves safe in PKD patients

Alicaforsen enters new phase II trial in active ulcerative colitis

NeoPharm terminates license agreement with Pharmacia

Inflazyme and Aventis expand respiratory drug development collaboration

Prehospital TNKase treatment of heart attack feasible and faster than in-hospital treatment

New PAR1 antagonists discovered by Eisai scientists

Wyeth claims 5-HT1A antagonists for cognitive disorders, schizophrenia, etc.

Novel muscarinic antagonists and their use in Parkinson's disease and other disorders

Series of esterase-susceptible anticoagulants covered by ARYx patent

Guanidine-based insulin sensitizers identified by AstraZeneca researchers

Wyeth presents novel dopamine D2 modulators with antipsychotic activity

Identification of new 5-HT6 ligands with utility in schizophrenia described by Wyeth

Compounds with dual 5-HT reuptake-inhibitory and 5-HT1A-antagonist activity

Integrin antagonist demonstrates significant antitumor/antimetastatic activity

MX-7091: a selective MKP-1 inhibitor with potential in anticancer therapy

Differentiation/involution-inducing agents in development at Maxia for breast cancer

Korean researchers select novel HDAC inhibitor for further evaluation as potential cancer therapy

Specific, orally available ETA receptor antagonist reported to have potential in cancer